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Introduction: Serum profiling using proteomic techniques has great potential to detect biomarkers that might
improve diagnosis and predict outcome for breast cancer patients (BC). This study used surface-enhanced laser
desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) to identify differentially expressed proteins
in sera from BC and healthy volunteers (HV), with the goal of developing a new prognostic biomarker panel.
Methods: Training set serum samples from 99 BC and 51 HV subjects were applied to four adsorptive chip surfaces
(anion-exchange, cation-exchange, hydrophobic, and metal affinity) and analyzed by time-of-flight MS. For validation,
100 independent BC serum samples and 70 HV samples were analyzed similarly. Cluster analysis of protein spectra was
performed to identify protein patterns related to BC and HV groups. Univariate and multivariate statistical analyses
were used to develop a protein panel to distinguish breast cancer sera from healthy sera, and its prognostic potential
was evaluated.
Results: From 51 protein peaks that were significantly up- or downregulated in BC patients by univariate analysis,
binary logistic regression yielded five protein peaks that together classified BC and HV with a receiver operating
characteristic (ROC) area-under-the-curve value of 0.961. Validation on an independent patient cohort confirmed
the five-protein parameter (ROC value 0.939). The five-protein parameter showed positive association with large
tumor size (P = 0.018) and lymph node involvement (P = 0.016). By matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) MS, immunoprecipitation and western blotting the proteins were identified as a fragment
of apolipoprotein H (ApoH), ApoCI, complement C3a, transthyretin, and ApoAI. Kaplan-Meier analysis on 181 subjects
after median follow-up of >5 years demonstrated that the panel significantly predicted disease-free survival (P = 0.005),
its efficacy apparently greater in women with estrogen receptor (ER)-negative tumors (n = 50, P = 0.003) compared to
ER-positive (n = 131, P = 0.161), although the influence of ER status needs to be confirmed after longer follow-up.
Conclusions: Protein mass profiling by MS has revealed five serum proteins which, in combination, can distinguish
between serum from women with breast cancer and healthy control subjects with high sensitivity and specificity. The
five-protein panel significantly predicts recurrence-free survival in women with ER-negative tumors and may have value
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The diagnosis of breast cancer relies on an integrated
approach using clinical and physical examinations, im-
aging mammography and ultrasound, and histopathology.
Although serum biomarkers have not yet played a major
role in breast cancer diagnostic or prognostic practice
[1,2], an effective biomarker panel in an easily accessible
biological fluid would be a valuable and minimally invasive
adjunct to other clinical and pathological approaches [3].
As whole blood provides a dynamic representation of
physiological and pathological status, serum or plasma
represents the most extensively studied biological matrix
for cancer biomarkers [4]. Therefore, analysis of the serum
or plasma proteome may be an important step to achieve
accurate diagnosis or prognosis.
For breast cancer biomarker discovery, proteins and
peptides have been identified in breast cancer cell lines
[5-7], nipple aspirate fluid [8,9], and normal, benign, prema-
lignant, and malignant breast tissue [10-13], in addition to
serum and plasma [1,4,14]. Numerous proteomics-based
studies of serum and plasma have reported discriminatory
peptide/protein ion peaks, either as identified proteins or
on the basis of their mass/charge (m/z) values, for breast
cancer diagnosis or prognosis. However, not all have re-
ported protein identities for the discriminatory ion peaks.
This study used surface-enhanced laser desorption/
ionization time-of-flight (SELDI-TOF) mass spectrometry
(MS) protein chip technology to discover a unique combin-
ation of serum biomarkers for breast cancer and confirm
them in an independent sample set. The markers were
identified by matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF)/TOF MS and verified im-
munologically. We also investigated the association
between this serum protein panel and patient outcome
to determine its potential prognostic utility.Methods
Serum samples
The study involved a total of 320 human serum specimens
and was approved by the Human Research Ethics Committee
of the Northern Sydney Local Heath District, Sydney,
Australia. The training set samples from patients diagnosed
with breast cancer (BC, n = 99) and control samples from
healthy volunteers (HV, n = 51) were obtained from the
Kolling Institute Breast Tumour Bank, at the Royal
North Shore Hospital, Sydney, Australia. The validation
set consisted of 100 independent BC serum samples
from the Australian Breast Cancer Tissue Bank, Sydney,
Australia and 70 HV samples. Sample sizes were estimated
to allow the detection of a difference of at least 25% in
a measured parameter between sample groups at the
5% significance level (α = 0.05) with a statistical power
of at least 0.8, assuming group coefficients of variationof 50% (σ = 0.5). All patients whose tumor samples (or
healthy tissue samples) are deposited into either of the
two tissue banks used in this project had given prior
written informed consent to the banking of their tissue
and its use in any future research projects. Therefore
additional patient consent was not required for this
specific project. The median ages of patients included
in the training and validation sets were 59 (range 28 to
92) and 58 (31 to 86), respectively. For HV control
groups, serum samples were age-matched to BC samples
within five-year age brackets. All sera were stored at -80ºC
until analyzed by SELDI-TOF MS.
Preparation of serum sample and protein chips for
SELDI-TOF MS
All serum samples were initially denatured in buffer con-
taining 8 M urea, 1% CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfate) and analyzed by
TOF MS on SELDI protein chip arrays (Bio-Rad, Hercules,
CA, USA) as previously described [15]. Four chip types
with different adsorptive surfaces were used: Q10 (strong
anion-exchange), Cu2+-IMAC30 (immobilized metal affin-
ity capture), CM10 (weak cation-exchange), and H50
(hydrophobic). The four chip types were pre-equilibrated
twice for 5 min with 5 μl of binding buffer (50 mM Tris-
HCl pH 8.0 for Q10; phosphate-buffered saline (PBS)
pH 7.2 for IMAC30; 50 mM sodium acetate pH 6.0 for
CM10; 10% acetonitrile (ACN) containing 0.1% trifluor-
oacetic acid (TFA) for H50). Denatured serum protein
samples were diluted 1:5 with the respective binding
buffers and 5 μl of each diluted sample was pipetted
onto the chips. All samples were analyzed in duplicate.
Chips were then incubated with shaking for 90 min at
room temperature (settings: form 20, amplitude 4) on a
MicroMix 5 (EURO/DPC Instrument Systems, Flanders,
NJ, USA). After washing twice with the binding buffer,
each spot was treated with 2 × 1 μl of 50% sinapic acid
(Sigma-Aldrich, St Louis, MO, USA) in 50% ACN, 0.5%
TFA and air dried.
MS serum protein profiling and data analysis
All mass spectra were obtained in the m/z range of
2,500 to 70,000 with the ProteinChip SELDI System
Enterprise Edition (Bio-Rad). Spectra were averaged from
583 laser shots evenly distributed across each spot. Mean
values from duplicate spectra for each sample were used in
all subsequent analyses. The m/z value for each peak was
determined using external calibration with protein stan-
dards: bovine insulin (5,734.51 Da), equine cytochrome
c (12,361.96 Da), equine apomyoglobulin (16,952.27 Da)
and bovine carbonic anhydrase (29,023.70 Da) from
Sigma-Aldrich. After calibration, spectra were baseline-
subtracted and normalized using the total ion current
between 2,500 and 30,000m/z. Of the original 320 samples,
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the normalization criteria. A total of 602 spectra were
subjected to full analysis (301 samples: BC = 187 and
HV = 114, in duplicate) on each of four chip types
(total = 2,408 spectra).
Clustering analysis of protein peaks (ProteinChip Data
Manager version 4.1, Bio-Rad) was performed to identify
protein patterns related to BC and HV groups. Data
analysis across all four protein chip types was achieved
using univariate analysis of individual peaks by Mann-
Whitney U test (IBM SPSS version 20.0, IBM Corp.,
Armonk, NY, USA). For initial discovery, biomarker panels
were developed on the training data set of 99 BC and
51 HV samples. All protein peaks that significantly dis-
criminated BC from HV at P <0.005 were then subjected
to multivariate analysis using forward and reverse binary
logistic regression (SPSS) to develop the training model.
The discriminatory power of each putative serum bio-
marker was further described using receiver operating
characteristic (ROC) area-under-the-curve (AUC) analysis
[10,16]. External validation was also carried out using an
independent set of 100 BC and 70 HV serum samples
aged-matched within five-year age brackets.
Protein peak identification
Immunological validation of protein biomarkers and pro-
tein peak identification was achieved by immunodepletion
using Protein G Dynabeads (Life Technologies Corp.,
Carlsbad, CA, USA). For complement C3a des-arginine
anaphylatoxin (C3a-desArg), 1.5 mg of Protein G beads
was incubated with 5 μg of anti-C3a/C3a desArg mouse
monoclonal antibody (Abcam, Cambridge, UK) and incu-
bated for 30 min at room temperature with rotation. After
washing with 200 μl of PBS containing 0.02% Tween 20 to
remove free antibody, the immobilized antibody was
added to 50 μl of diluted serum samples and incubated for
2 h at 4ºC with rotation. The captured protein-antibody
complex was washed twice with 200 μl of PBS and the
bound protein eluted at room temperature in 20 μl of
0.1 M glycine, pH 3.0. The starting material, immunode-
pleted samples and the eluted proteins were monitored by
SELDI-TOF MS on normal-phase NP20 chips (Bio-Rad).
For apolipoprotein CI (ApoCI) and transthyretin (TTR) a
similar procedure, using rabbit anti-ApoCI polyclonal
antibody (Abcam) and anti-prealbumin monoclonal anti-
body (Abcam) respectively, was followed.
Immunological confirmation of serum protein markers by
western blotting
Three putative protein markers were also examined by
western blotting. Human sera from BC (n = 4) and HV
(n = 4) were separated by 4 to 12% SDS-PAGE (Invitrogen,
Carlsbad, CA, USA) and transferred to polyvinylidene
difluoride membrane (Bio-Rad). Membranes were blockedfor 1 h at room temperature with 5% skim milk. Western
blotting was conducted using primary antibodies against
C3a/C3a desArg (mouse monoclonal, Abcam) or ApoCI
(rabbit polyclonal, Abcam) at 1:1000 dilution and TTR
(mouse monoclonal antibody to human prealbumin,
Abcam) at 1:2000 in 5% skim milk. Secondary antibodies,
peroxidase-linked anti-mouse immunoglobulin G (IgG)
(1:2000) or anti-rabbit IgG (1:2000), respectively, were
added for 1 h at room temperature and protein bands
were visualized by enhanced chemiluminescence using
Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare Life Sciences, Little Chalfont,
UK). Western blot data were imaged using the LAS
3000 imaging system (Fujifilm, Stamford, CT, USA) and
the images were analyzed with MultiGauge version 3.0
software (Fujifilm). Correlations between densitometric
analysis by western blotting and SELDI-MS peak inten-
sities were also examined.Protein identification by MALDI-TOF/TOF MS
Human sera were fractionated on a weak cation-exchange
HiTrap FF column (GE Healthcare) with a linear gradient
from 0 to 600 mM NaCl in 25 mM Na acetate pH 6.0
using an ÄKTA Purifier system (GE Healthcare). Fraction-
ated proteins were monitored by SELDI-TOF MS on
NP20 chips. Fractions containing a 3.8 kDa putative bio-
marker were further purified using reverse-phase liquid
chromatography (RP-LC) on a 250 × 4.6 mm Jupiter 5 μm
300-Å C18 column (Phenomenex, Lane Cove, Australia),
eluted with a 30-min linear gradient from 15 to 60% ACN
in 0.1% TFA at 1.5 ml/min. After freeze drying the fraction
containing the protein of interest, it was reconstituted in
15% ACN, 0.1% TFA and analyzed using MALDI-TOF
peptide mass fingerprinting (PMF) and MS/MS on a
Bruker UltrafleXtreme MALDI-TOF/TOF MS (Bruker
Daltonics, Bremen, Germany), using an MTP AnchorChip
target (Bruker Daltonics) and α-cyano-4-hydroxycinnamic
acid as matrix.
To identify the protein peak at 28.2 kDa, human sera
were fractionated by anion-exchange chromatography using
Q ceramic HyperD F sorbent (BioRad) by means of step-
wise pH elution from pH 9 to pH 4 as previously described
[17]. Fractionated proteins were monitored by SELDI-TOF
MS on NP20 chips. Final identification was achieved
after liquid chromatography (Ultimate 3000 nanoLC,
Thermo Fisher Scientific, Waltham, MA, USA) on an
Acclaim PepMap RSLC C18 2 μm, 100 Å, nanoViper
guard (75 μm× 20 mm) and analytical (75 μm× 150 mm)
column (Thermo Fisher Scientific), using a 2 to 79%
ACN/0.05%TFA gradient at 300 nl/min. Fractions were
spotted onto an MTP AnchorChip target (Bruker), and
analyzed by MS/MS using the UltrafleXtreme MALDI-
TOF/TOF MS (Bruker).
Table 1 Patient characteristics
Training set Validation set
Number of patients 92 95











T ≤2 cm 34 65


















HER2, human epidermal growth factor receptor 2; IDC, invasive ductal
carcinoma; ILC, invasive lobular carcinoma.
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Univariate analysis by the Mann-Whitney U test (SPSS
Inc., Chicago, IL, USA) was used to distinguish sera
from patients with breast cancer from healthy controls.
Further multivariate analysis by binary logistic regression
was also achieved by SPSS. The correlation between the
levels of the five serum markers, individually and in com-
bination, with tumor pathologic variables (histological
grade, tumor size, lymph node involvement, estrogen
receptor (ER) and progesterone receptor (PR) status
and human epidermal growth factor receptor 2 (HER2)
overexpression) were investigated by multiple linear
regression (SPSS). We defined the median of combined
peak intensity for all group patients as the cutoff value
for the survival data analysis. Disease-free survival ana-
lyses were estimated using the Kaplan-Meier method
and the model differences in survival time were tested
using the log-rank test.
Results
Patient characteristics
Sera analyzed in this study formed two sample sets, the
training and validation groups. Of 320 serum samples
(BC = 199, HV = 121) selected for both the training and
validation sets, 187 BC and 114 HV were fully analyzed,
19 samples (12 BC, 7 HV) being excluded because their
mass spectra did not meet the normalization criteria.
The pathological characteristics of the tumors including
histological type and grade, size, hormone receptor (ER
and PR), HER2 status as well as lymph node status are
presented in Table 1. More than 90% of cancer patients
had an invasive tumor and more than half of these were
of high histological grade. Clinical management of all
patients was based on standard guidelines [18] and
treatment involved radiotherapy, chemotherapy, hormone
therapy, and trastuzumab in patients with HER2-positive
tumors. Median follow-up for ER-positive patients (n = 131)
was 5.10 years (range: 0.16 to 9.50) and for ER-negative
patients (n = 50), 5.05 years (range: 0.12 to 9.42).
Establishment of a putative biomarker panel
A total of 320 serum samples were used in this study
generating 2,560 mass spectra. After normalization,
spectra from 19 subjects were excluded from the data
analysis, leaving 2,408 spectra (4 chip surfaces, 187 BC
and 114 HV, in duplicate) available for full data analysis.
From the 92 BC and 46 HV serum samples included in
the training set, 57 common peaks from H50 chips, 62
from IMAC30, 70 from CM10, and 57 from Q10, were
determined by clustering analysis using expression dif-
ferential mapping (Bio-Rad). Of these, a total of 51
peaks - 14 from H50 (Figure S1A in Additional file 1),
12 from IMAC30 (Figure S1B in Additional file 1), 13
from CM10 (Figure S1C in Additional file 1), and 12from Q10 (Figure S1D in Additional file 1) - were dif-
ferentially expressed as determined by Mann-Whitney
U test (P <0.005, Table S1 in Additional file 2). When
tested for their ability to discriminate between BC and HV
samples, these peaks gave individual ROC-AUC values
ranging from 0.65 to 0.84 (Table S1 in Additional file 2).
Note that for downregulated proteins, ROC-AUC values
are expressed as (1-value). The 51 significant peaks were
then tested in a forward and reverse binary logistic regres-
sion analysis with 10-fold cross-validation.
The final training model gave an average ROC-AUC
value of 0.961 (Figure 1A, Table 2) for a combination of
five peaks (m/z 3808, m/z 6624, m/z 8916, m/z 13870,
Figure 1 Receiver operating characteristic (ROC) curve analysis comparing the performance of five-protein and four-protein panels on
training and validation data sets. When used to distinguish serum samples from breast cancer patients (BC) from those from the healthy volunteer
(HV) group, the average ROC area under the curve (AUC) was 0.961 for the five-protein parameter in the training set (A) and 0.939 in the independent
validation set (B). For the four-protein parameter, the average value of ROC-AUC was 0.935 in the training set (C) and 0.954 in the validation set (D).
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of peaks with m/z 3808, m/z 8916 and m/z 13870 were
significantly higher in BC serum than in HV serum
(P = 0.002, P <0.001, and P = 0.001, respectively), while the
intensities of peaks with m/z 6624 and m/z 28268 were
significantly lower in BC serum than in HV (P = 0.001 and
P = 0.025) (Figure 2).
For validation, the five putative biomarkers were tested
using an independent data set of mass spectra derived
from 100 BC serum samples and 70 age-matched HVs,
of which 1,304 spectra (95 BC and 68 HV in duplicate, 4
chip surfaces) could be analyzed after normalization.Table 2 Diagnostic performance of five-protein and four-prot
Model Cancer patients Healthy volunteers Sensitiv
Five-protein panel
Training set 92* 46* 97.6
Validation set 95* 68* 86.8
Four-protein panel
Training set 92* 46* 90.5
Validation set 95* 68* 92.6
*included mass spectrometry (MS) spectra after normalization. ROC-AUC, receiver oTesting the five-protein panel derived from the training
set on the independent sample set gave an average
ROC-AUC value of 0.939 (Figure 1B). The sensitivity
and specificity of the combined five-protein panel were
86.6% and 92.4% respectively, and overall accuracy was
89.4% (Table 2).
In an attempt to simplify the model, we also tested a
four-protein panel (m/z 6624, m/z 8916, m/z 13870, and
m/z 28268) that omitted the m/z 3808 peak (for which
we had no immunological confirmation), to compare
with the original training model of five proteins. By
multivariate analysis, the simplified model applied to theein classification models
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Figure 2 Relative abundance of the serum proteins used to develop the five-protein parameter. Significantly different peak intensities observed
between breast cancer patient (BC) and healthy volunteer (HV) samples on the combined training and validation sets: (A) m/z 3808 on CM10 weak
cation-exchange surface; (B) m/z 6624 on H50 hydrophobic surface; (C) m/z 8916 on Q10 strong anion exchange surface; (D) m/z 13870 on IMAC30
immobilized metal affinity surface; (E) m/z 28268 on Q10 strong anion exchange surface. Data were analyzed by the Mann-Whitney U test.
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(Figure 1C). The sensitivity and specificity of the com-
bined four-protein panel were correspondingly reduced
to 90.5% and 79.9%, respectively (Table 2). However,
testing the four-protein panel on the validation set gave
an average ROC-AUC value of 0.954 with sensitivity and
specificity of 92.6% and 82.4% (Figure 1D, Table 2).
Therefore the simplified model consisting of four pro-
teins, omitting the m/z 3808 peak, also has considerable
discriminatory power.
Identities of protein peaks confirmed by immunodepletion
and western blotting
Serum protein peaks at m/z values similar to 6,624 and
8,916 have been previously reported in the literature
from other MS-based studies, identified as ApoCI and
C3a-desArg, respectively [19-21]. To confirm these iden-
tities for our peaks of m/z 6624 and 8916, proteins were
enriched by immunoprecipitation from serum extracts
using immobilized anti-ApoCI or C3a/C3a desArg anti-
bodies. Both the immune-depleted serum and the immu-
noprecipitated proteins were analyzed by SELDI-TOF
MS. The peak at m/z 6624 (Figure 3A) was fully depleted
by ApoCI antibody and recovered in the immunopre-
cipitate, and the peak at m/z 8916 (Figure 3B) was
approximately 80% depleted by the C3a/C3a-desArg
antibody and also recovered in the immunoprecipitate,
confirming the identities of these protein peaks. Inter-
estingly, a peak at m/z 6428 co-precipitated with full-length
ApoCI (m/z 6624), suggesting that m/z 6428 is related
to ApoCI. For the peak at m/z 13870, assumed to be
transthyretin (TTR, also known as prealbumin), immu-
noprecipitation with immobilized anti-human prealbumin
antibody partially depleted the serum extract, and again
the depleted protein was recovered in the precipitate
(Figure 3C).Figure 3D compares the levels of ApoCI, C3a/C3a-
desArg and TTR by western blotting between four BC
and four HV serum samples, with quantitation of band
densities shown in Figure 3E, correlations between SELDI
peak intensity and densitometric analysis of western blot-
ting are shown in Figure 3F, G and H for the three proteins,
indicating strong positive relationships between MS peak
intensity for peaks identified as ApoCI (m/z 6624), C3a-
desArg (m/z 8916), and TTR (m/z 13870), and their quanti-
tation by immunoblot.
Protein peaks identified by MALDI-TOF MS/MS
To identify the 3.8 kDa protein, it was purified using
cation-exchange and reverse-phase liquid chromatography
(RP-LC) and analyzed by MALDI-TOF MS. Figure 4A
shows a SELDI-TOF spectrum of the 3.8 kDa peptide
from whole serum (upper panel) and the peptide after
purification by two chromatographic procedures using
HiTrap CM FF followed by RP-LC (lower panel). MALDI-
TOF/TOF MS/MS indicated a fragment of apolipoprotein
H (ApoH or beta2 glycoprotein 1, P02749) based on a
single tryptic peptide of m/z 1446 (Table S2 in Additional
file 3), or 38% of the mass of the peptide observed by
SELDI-TOF MS (m/z 3808). Since full-length human
ApoH is 38.3 kDa, the m/z 3808 biomarker peptide repre-
sents a small fragment of ApoH. It was not possible to
analyze this ApoH fragment immunologically as no
antibody specific for the identified sequence is currently
available.
The 28.2 kDa protein was purified by anion exchange
and RP-HPLC and the fractions containing this protein
were analyzed by SELDI-TOF MS using NP20 Protein
Chip arrays. Figure 4B shows SELDI mass spectra for this
peak before and after two chromatographic procedures.
MALDI-TOF/TOF MS identified full-length mature hu-





Figure 3 Identification of serum proteins by immunodepletion and western blotting. Proteins representing peaks at m/z 6624, m/z 8916 and
m/z 13870 were immunodepleted from serum extracts using monoclonal antibodies against (A) apolipoprotein CI (ApoCI), (B) C3a/ C3a des-arginine
anaphylatoxin (C3a-desArg) or (C) transthyretin. The starting material (Starting, upper panel), the immunodepleted sample (Depleted, middle panel)
and the eluted fraction (Recovered, lower panel) were analyzed on NP20 arrays by surface-enhanced laser desorption/ionization time-of-flight
(SELDI-TOF) mass spectrometry (MS). (D) Western blotting for ApoCI, C3a/C3a-desArg and transthyretin were performed on four healthy volunteer (HV)
samples and four breast cancer patient (BC) samples. (E) Mean band densities (+standard deviation (SD)) derived from the blots shown in panel D
(n = 4 for all groups). (F-H) Association between SELDI peak intensities and western blotting band densities for individual HV and BC serum samples
(n = 8), indicating strong correlations for (F) ApoCI, (G) C3a-desArg and (H) transthyretin.
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Table S2 in Additional file 3. Western blotting for ApoAI
showed no significant difference in band intensity between
four BC and four HV samples (data not shown).
The immunoprecipitated protein of m/z 13870 was
also confirmed as TTR by MALDI-TOF/TOF MS/MS
after tryptic digestion (Table S2 in Additional file 3) giving
three peptide sequences mainly at the C-terminus of TTR.
By MALDI-TOF MS analysis the main peak (undigested)
appeared at m/z 13756 (not shown), smaller than the size
of 13,870 determined by SELDI-TOF MS.Prognostic value of the serum biomarker panel
The median follow-up periods for patients in the training
and validation sets were 6.1 (0.16 to 9.50) years and 4.8
(0.12 to 6.58) years, respectively. Of 181 patients with
follow-up data available, 86 were in the training set and 95
in the validation set. During the follow-up period, recur-
rence of breast cancer occurred in 32 patients (17.7%) and
death occurred in 33 patients including 22 (12.2%) who
died due to breast cancer and distant metastases, and 11
(6.1%) who died from other causes. Disease-free survival
was calculated from the time of surgery to the time that
AB
Figure 4 Surface-enhanced laser desorption/ionization (SELDI)
profiles before and after protein purification. (A) m/z 3808: the
starting material (upper panel) and the purified fraction (lower
panel) after weak cation chromatography and reverse-phase
high-performance liquid chromatography (RP-HPLC) were analyzed
on NP20 arrays. (B) m/z 28268: the starting material (upper panel),
and the purified fraction (lower panel) after strong anion-exchange
and RP-HPLC were analyzed on NP20 arrays.
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the last follow-up for all censored patients. Survival
estimates were analyzed by the Kaplan-Meier method
and compared by the log-rank test. We defined the
median value of the combined serum values for the
five- or four-peak panels (derived by SPSS) for all breast
cancer patients as the cutoff value for each survival data
analysis and compared the outcomes produced by the two
models (five-peak panel vs. four-peak panel).
A high value for the combined five-protein parameter
was significantly associated with poor disease-free survival
(P = 0.005, Figure 5A), whereas survival estimates calcu-
lated from the four-protein panel showed no significant
difference between high and low values of the parameter(P = 0.076, Figure 5B). When women with ER-negative
and ER-positive tumors were examined separately, the
significant survival effect seen in the five-protein model
was strengthened in the ER-negative group, in whom a
high value for the combined parameter was significantly
associated with poor disease-free survival (P = 0.003,
Figure 5C). In contrast, in ER-positive patients the prog-
nostic value of the combined parameter was no longer
significant (P = 0.161, Figure 5D).
We also examined the association of the five-protein
panel with clinical pathologic variables such as histological
grade, tumor size, lymph node status and hormone recep-
tor (ER and PR), and HER2 status, summarized in Table 1.
Multiple linear regression was used to test the correlation
between the individual serum protein levels (measured by
SELDI-TOF MS) and the combined five-protein panel,
and these clinicopathological characteristics (Table 3).
Based on this analysis, the five-protein panel was sig-
nificantly associated with tumor size (P = 0.018) and
lymph node involvement (P = 0.016), further suggesting
its potential to contribute to breast cancer prognosis.
Discussion
Patient blood samples are an ideal source of disease bio-
markers owing to their ease of access, and many studies
have identified possible candidates, but few have over-
come validation and reproducibility issues to achieve
clinical application [22]. In the present study, we used
protein chip mass spectrometry to discover and identify a
unique panel of five serum proteins that, in combination,
discriminate between sera from breast cancer patients and
healthy volunteers with high sensitivity and specificity.
The five-protein panel was developed by multivariate ana-
lysis of a larger group of proteins found to be significantly
regulated in breast cancer, and validated on an independ-
ent data set. Whereas the sensitivity of the five-protein
parameter was somewhat lower in the validation set than
the training set, the specificity was slightly higher in the
validation set. A simplified four-protein panel, from which
data for a fragment of ApoH (m/z 3808) was omitted,
showed considerably less specificity than the five-protein
panel on both data sets (that is, it classified an increased
number of false positives), but remained highly sensitive
in detecting samples from women with BC.
When tested for its ability to predict disease-free patient
survival, the median value of the five-protein parameter
separated patients into significantly different groups, those
with values above the median showing more rapid disease
recurrence than those with values below the median.
Using the four-protein parameter this significant discrim-
ination was lost. Interestingly, the prognostic value of the
five-protein parameter appeared to be restricted to women
with ER-negative tumors, none of whom showed disease
recurrence over the monitoring period if their five-protein
Figure 5 Kaplan-Meier survival analyses. (A) Patients with values of the five-protein parameter greater than the median (gray line) showed
significantly worse disease-free survival than those with values below the median (black line) (B) Similar data for the four-protein parameter, omitting
the m/z 3808 peak (apolipoprotein H (ApoH) fragment). (C) In women with estrogen receptor (ER)-negative tumors, values greater than the median for
the five-protein parameter (gray line) were associated with significantly worse survival than values below the median (black line); (D) in women with
ER-positive tumors, this survival difference was lost.
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this ER-negative group, almost half of the women had
disease recurrence within the monitoring period if their
five-protein parameter was above the median value. These
distinctions were not seen among women with ER-
positive tumors. Therefore we conclude that, in women
with ER-negative tumors, the five-protein parameter
appears to have strong prognostic value within the firstTable 3 Multiple linear regression analysis of the association
combined value with clinical pathologic features
Tumor variables
ApoCI C3a-desArg Tr
Grade (G1, n = 22; G2, n = 64; G3, n = 96) 0.781 0.908 0.8
Tumor size (T ≤2 cm; T >2 cm) 0.314 0.867 0.0
LN (positive, n = 79; negative, n = 78) 0.182 0.503 0.3
ER (positive, n = 131; negative, n = 50) 0.550 0.756 0.1
PR (positive, n = 121; negative, n = 63) 0.723 0.774 0.0
HER2 (positive, n = 38; negative, n = 133) 0.509 0.280 0.9
ApoCI/AI/H, apolipoprotein CI/AI/H; C3a-desArg, C3a des-arginine anaphylatoxin; LN
HER2, human epidermal growth factor receptor 2.five years. It is recognized that, owing to the use of endo-
crine therapy, ER-positive disease is less likely to relapse
early [23]; therefore longer follow-up will be required to
ascertain prognostic utility in this subgroup.
Using a combination of mass spectrometry and immuno-
logical methods, the proteins were identified as a fragment
of ApoH, ApoCI, C3a-desArg, TTR, and ApoAI. Among
this five-peak panel, three (C3a-desArg, TTR and ApoH)between five putative biomarker proteins and their
P value
ansthyretin ApoAI ApoH fragment Combined parameter
62 0.876 0.836 0.697
04 0.921 0.516 0.018
97 0.119 0.499 0.016
51 0.517 0.124 0.341
10 0.171 0.340 0.825
68 0.018 0.733 0.087
, lymph node involvement; ER, estrogen receptor; PR, progesterone receptor;
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pared to that of HV subjects, while ApoCI and ApoAI
were decreased in cancer. Each of these serum proteins
has previously been associated with breast cancer in vari-
ous studies, but this study is the first to identify the unique
prognostic value of combining their serum concentrations
into a single parameter. The combined value was also
significantly associated with tumor size (P = 0.018) and
lymph node involvement (P = 0.016).
Human complement C3 is the most abundant comple-
ment protein in human serum. C3 convertase exists in
two forms (C3bBb and C4bC2a) and cleaves only C3, a
central molecule of the complement system, between
residues 726 to 727 (Arg-Ser), generating C3b and an N-
terminal fragment, C3a, (8.9 kDa) [24]. C3a has high
biological activity and is able to trigger the degranulation
of mast cells and basophils, which produces a local
inflammatory response. The desArg form represents a
stable inactivated form of complement C3a. C3a-desArg
was previously observed to be higher in BC sera com-
pared to healthy controls in several studies [14,21,25,26]
with a m/z range of 8900 to 8941 observed on IMAC-Ni
protein chips. Increased C3a-desArg serum levels have
also been reported in hepatocellular and colorectal cancer
[27,28]. In our study, we identified this protein at m/z
8916 on Q10 chips alone, with significant discrimination
between breast cancer patients and healthy controls.
Transthyretin (TTR, also known as prealbumin) is a
liver-derived secreted protein and is the major serum
carrier of thyroid hormones, thyroxine and tri-iodothyr-
onine. TTR is also involved in the transport of retinol
through its interaction with retinol-binding proteins.
Differential levels of TTR in serum have been linked to
several cancers, including breast [29,30], ovarian [31]
and hepatocellular carcinomas [32]. Five isoforms of
TTR have been previously demonstrated by MALDI
analysis after immunoaffinity capture [33]: full-length
TTR (13,758 Da), a form truncated N-terminally by 10
residues (12,210 Da), and the three modified isoforms
(Cys-TTR at m/z 13876, CysGly-TTR at m/z 13924, and
glutathionylated-TTR at m/z 14062). In our study, we
identified the peak at m/z 13870 as full-length TTR;
however, a peak at m/z 13756 detected by Q10 protein
chip was also significantly upregulated in the serum of
breast cancer patients (Table S1 in Additional file 2). Only
the isoform that most likely corresponds to Cys-TTR (m/z
13870 in this study) was computationally selected into the
final five-protein panel.
Apolipoproteins bind lipids to form lipoproteins that
transport the lipids through the lymphatic and circulatory
systems. Serum and plasma lipoprotein metabolism is
regulated and controlled by the specific apolipoprotein
(Apo-) constituents of the various lipoprotein classes
such as ApoAI, ApoCI, ApoH (beta2 glycoprotein) andothers. Several classes of apolipoprotein in serum or
plasma have been discovered as putative breast cancer
biomarkers using proteomic techniques including SELDI-
TOF, MALDI-TOF/TOF, 2D-iTRAQ-LC-MS/MS, and
2D-LC MS/MS [19-21,30,34]. We observed that levels
of ApoAI and ApoCI were significantly downregulated
in breast cancer patients, while a peptide identified as a
fragment of ApoH was significantly higher in BC. A
previous study also identified both ApoAI and ApoCI by
SELDI-TOF as part of a multiprotein panel evaluated as a
predictor of metastatic relapse in high-risk BC patients
[20]. Decreased serum ApoAI has also been found in
other types of cancer including ovarian [31] and bladder
carcinomas [30]. ApoAI and ApoAI mimetic peptides
have been shown to inhibit tumor development in a
mouse model of ovarian cancer, suggesting that ApoAI
may not only have potential as a biomarker, but may also
have therapeutic utility in this disease [35]. Serum ApoCI
has also been previously found to be decreased in breast
cancer patients compared to healthy control groups [21].
ApoH or beta2 glycoprotein was recognized immuno-
logically over 30 years ago as being increased in the serum
of breast cancer patients [36], but the 3808 Da ApoH
fragment that we found to be increased in breast cancer
sera has not been reported previously.
Conclusions
While many serum proteins have been found to differ
significantly in concentration between healthy subjects
and those with breast cancer, they have little discrimin-
atory or prognostic value when used as single markers.
In contrast, this study has shown that patients with
greater than median values of a combined biomarker
calculated from the concentrations of five serum proteins
have significantly shorter disease-free survival times
than those with below-median values of this parameter.
Notably, the prognostic value of this five-protein param-
eter appeared to be greatest in women with ER-negative
tumors. Therefore in this patient group the combined bio-
marker may show clinical utility as an adjunct to other
pathological variables in predicting patient outcome. This
needs to be confirmed in larger patient cohorts, and the
development of the new marker panel in an immunoassay
format (for example, a multiplexed ELISA) will facilitate
its further evaluation as a novel tool in the management
of patients with breast cancer.
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